Clinical Trials for White blood cell infusions to treat cancer

The Wake Forest Clinical trial for granulocyte infusions to cure cancer was cancelled but a new South Florida clinical trial is proceeding. The clinical trials are to see if simple blood transfusions can transfer cancer immunity from people with strong cancer immunity to those without such strong immunity. This procedure has been shown to cure cancer in mice. A mouse is given a lot of cancer and then is cured of it with blood transfusions from super-immune mice.
Here is the link to the cancelled clinical trial.

South Florida Bone Marrow/Stem Cell Transplant Institute is sponsoring the white blood cell transfusion clinical trial. The phase I and II trial that is running now.

>South Florida Bone Marrow/Stem Cell Transplant Institute page on the granulocyte anti-cancer clinical trial

The South Florida Institute information page for cancer patients cites the Wake Forest work and history of the project.

This is the cancer treatment from Zheng Cui, which has been covered extensively at this site.
Update on the GIFT cancer treatment

White blood cells from a strain of cancer-resistant mice cured advanced cancers in ordinary laboratory mice, researchers at Wake Forest University School of Medicine reported

at the SENS3 conference in Sept 2007, Dr. Cui presented the next logical step in his research: work demonstrating the existence of, and characterizing, high-potency cancer-killing granulocytes in humans. This same cancer killing cells provides mice with immunity to cancer.

A Phase I/II Study For the Use of White Blood Cells From Healthy Donor-Participants To Treat Subjects With Solid Cancers

About 75% of US population living today will not die of cancer. It is not uncommon that some people remain cancer-free into their 80s and 90s, even if they are regularly exposed to environmental carcinogens such as air pollutants, cigarette smoking, etc. A frequently asked but unanswered question is why these individuals do not get cancer. There has been a recent report of a colony of cancer-resistant mice developed from a single male mouse that unexpectedly survived challenges of lethal cancer cell injections. In these so-called spontaneous regression/complete resistant (SR/CR) mice, cancer cells are killed by rapid infiltration of leukocytes, mainly of innate immunity. This highly effective natural cancer immunity is inherited and mediated entirely by white blood cells. Moreover, this cancer resistance can be transferred to wild type mice through the transfer of various immune cell types including granulocytes.

This observation raises the possibility that infusion of white blood cells, particularly cells of innate immunity, is a viable anticancer therapy in humans as well.

This proposed trial will test whether white blood cell infusions from healthy unrelated donors can be used to treat cancer. The trial is designed to determine whether responses can be seen in cancer patients after infusion of HLA-mismatched white cells from healthy donors. It is important that the donors and recipients be unrelated and HLA-mismatched to avoid the possibility of transfusion-related Graft vs. Host Disease.

The white blood cells from the healthy donors are being collected via apheresis following granulocyte mobilization with dexamethasone and filgrastim. The investigators will refer to the white blood cells as ‘granulocytes’ because 75-90% of the white blood cells collected through the apheresis will consist of granulocytes.

The dose of at least 2×10 to the11th will be given from 4-5 donors at a rate of no more than one donor per day for each recipient. There will only be one infusion per day and no more than 5 infusions per week, but in many scenarios there may only be 3 days per week. Thus, a typical treatment in the study would span 1-2 weeks with up to a 4-day interval between 3rd and 4th infusion. After each infusion, the patients will be monitored carefully for possible adverse events. If adverse events occur at any time point during or after individual infusion, the treatment can be stopped until the adverse events can be managed. The daily dose of each infusion is a frequently used level that has a long safety record.

The trial will observe the subject’s cancer for 3 months after the granulocyte infusions are completed. Response at 90 days will be based on comparison of tumor measurements at baseline.

The trial has 3 major endpoints: dose response and tolerance, safety, and efficacy.